The short answer
The blood-brain barrier excludes most circulating peptides. Any claim that a peptide acts centrally requires it to cross, be transported, or act at a site outside the barrier, and which of those applies is rarely specified.
Key facts
- Barrier formed by
- Tight junctions between endothelial cells
- Excludes
- Most peptides and hydrophilic molecules
- Routes across
- Transporters, receptor-mediated transcytosis
- Exception sites
- Circumventricular organs
- Review
- Zhou 2021 (PMID 33470550)
- DSIP charge
- Strongly acidic, unfavourable
What the barrier is
Brain capillary endothelial cells are joined by tight junctions that prevent material passing between them, so anything entering must go through the cells rather than around them. That requires either lipid solubility sufficient to cross membranes or a specific transporter. Most peptides have neither.
Why charge makes it harder
Charged molecules do not partition into lipid membranes. DSIP is strongly acidic, carrying negative charge at physiological pH, which is among the least favourable profiles for passive entry. A neutral, small, lipophilic molecule crosses readily; a charged nine-residue peptide does not.
Research material referenced
DSIP 5mg, third-party HPLC tested
The routes that do exist
Specific transporters carry particular molecules across, and receptor-mediated transcytosis moves larger cargo by binding a receptor and being ferried through the cell. Both are selective. A molecule benefits only if a transporter or receptor recognises it, which is why brain penetration is engineered rather than assumed. Zhou and colleagues reviewed the strategies in 2021.
The sites where the barrier is absent
Circumventricular organs, including the area postrema, sit outside the barrier so they can sample blood directly. A circulating peptide can act there without crossing anything, and this is how incretin agonists produce central effects on nausea. It is a real route, and it reaches only a small number of specific structures.
Why this is the unstated assumption in the DSIP story
The original experiment introduced the peptide into the ventricles, directly into cerebrospinal fluid, bypassing the barrier entirely. That is a legitimate experimental route and it establishes nothing about whether the peptide reaches the brain from circulation. Any account of peripheral administration producing a central effect owes an explanation of how, and the literature does not supply one.
Why this generalises
Several compounds in this catalogue carry central claims: Semax, Selank, DSIP. Each faces the same question, and in each case the answer is either a transport route, a circumventricular site, or an assumption. Identifying which is a fair test to apply to any claim about a peptide acting on the brain.
Frequently asked questions
Why can't most peptides enter the brain?
Tight junctions force entry through endothelial cells, requiring lipid solubility or a specific transporter. Most peptides have neither.
Does charge matter?
Considerably. Charged molecules do not partition into membranes, and DSIP is strongly acidic, which puts it among the least favourable profiles.
How did the original DSIP experiment get around this?
It introduced the peptide into the ventricles, bypassing the barrier entirely, which establishes nothing about entry from circulation.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedZhou X et al., Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. WIREs Nanomed Nanobiotechnol 2021 (PMID 33470550)pubmed.ncbi.nlm.nih.gov
- PubMedGraf MV, Delta-sleep-inducing peptide (DSIP): an update. Peptides 1986 (PMID 3550726)pubmed.ncbi.nlm.nih.gov
- PubMedHuang KP et al., Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 2024 (PMID 38987598)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More DSIP (Delta Sleep-Inducing Peptide) articles
- What Is DSIP? The Nonapeptide Named for an EEG EffectDSIP is a nonapeptide isolated from rabbit blood in 1977 and named for an observed EEG effect. No gene, precursor or receptor has ever been identified.
- Does DSIP Actually Induce Sleep? What the Evidence ShowsDSIP is named for a sleep effect. The evidence has never firmed up: no gene, no receptor, and a literature its own reviewers call an unresolved riddle.
- How DSIP Was DiscoveredSchoenenberger and Monnier stimulated a sleeping rabbit's thalamus, collected the blood draining from its brain and isolated a peptide. The 1977 method.
- The Missing Biology: No Gene, No Precursor, No ReceptorFor an endogenous signalling peptide, DSIP is missing all three of the things that normally establish one. Why that absence matters more than any single study.
- What Delta Waves Are, and Why DSIP Is Named for ThemDelta waves are high-amplitude, low-frequency EEG activity below about 4 Hz, characteristic of deep non-REM sleep. What they measure and what they do not.